Table of Contents
Overview
New York, NY – July 15, 2025 – The Global Infection Control And Biosafety Products Market size is expected to be worth around USD 130.8 Billion by 2033, from USD 56.8 Billion in 2023, growing at a CAGR of 8.7% during the forecast period from 2024 to 2033.
The global infection control and biosafety products market is witnessing substantial growth, driven by increasing awareness of infection prevention, the rise in hospital-acquired infections (HAIs), and the growing demand for hygiene solutions in healthcare and laboratory environments. The market is expected to expand significantly during the forecast period due to heightened concerns over pathogen transmission, particularly in the wake of global pandemics.
Infection control products including disinfectants, sterilization equipment, personal protective equipment (PPE), and hand hygiene solutions are widely used across hospitals, diagnostic laboratories, pharmaceutical manufacturing units, and research institutions. Meanwhile, biosafety products such as biosafety cabinets, containment systems, and waste disposal units ensure the safe handling of infectious materials, especially in high-risk clinical and microbiological settings.
Governments and regulatory agencies are actively supporting infection control programs, further boosting market expansion. Technological advancements and the development of cost-effective and automated disinfection solutions are expected to create lucrative opportunities for manufacturers.
North America currently dominates the market due to strong healthcare infrastructure and regulatory enforcement. However, Asia Pacific is projected to register the fastest growth, driven by rising healthcare investments and infection control mandates.
The increasing need for effective infection prevention strategies continues to shape the future of the infection control and biosafety products market on a global scale.
Key Takeaways
- The global Infection Control and Biosafety Products Market is projected to grow from USD 56.8 billion in 2023 to approximately USD 130.8 billion by 2033, registering a compound annual growth rate (CAGR) of 8.7% during the forecast period.
- Disinfection products account for the largest segment, commanding 37% of the total market share, primarily driven by sustained demand for surface disinfectants, sanitizers, and cleaning wipes across healthcare and public settings.
- Hospitals and clinics represent the leading end-user segment, contributing to over 41% of the market share, due to the increasing focus on infection prevention, regulatory compliance, and patient safety initiatives.
- North America continues to dominate the global market, holding a significant 35.1% share equivalent to approximately USD 19.9 billion supported by its advanced healthcare infrastructure, stringent hygiene regulations, and widespread adoption of infection control protocols.
- The Asia-Pacific region is emerging as the fastest-growing market, propelled by rising investments in healthcare infrastructure, enhanced awareness regarding biosafety practices, and growing governmental focus on infection prevention and control across developing countries.
Segmentation Analysis
- Product Type Analysis: In 2023, the Disinfection Products segment led the market with over 37% share, driven by strong demand for surface disinfectants, hand sanitizers, and disinfectant wipes. Increased hygiene awareness and strict cleanliness protocols across healthcare settings have significantly boosted this segment. Simultaneously, the PPE segment witnessed substantial growth due to rising infection rates and global safety mandates, especially for N95 masks and nitrile gloves. Sterilization and surveillance equipment also gained traction due to their biosafety compliance roles.
- End-Use Analysis: In 2023, Hospitals and Clinics dominated the end-use segment, capturing more than 41% of the market share. This dominance is attributed to strict infection control policies, high patient volumes, and the prevalence of invasive procedures. The segment benefited from growing adoption of advanced disinfection systems, sterilization tools, and protective equipment. The COVID-19 pandemic further accelerated investments in infection control infrastructure, prompting medical institutions to adopt smart, technology-integrated biosafety solutions to meet evolving regulatory and operational requirements.
Market Segments
Product Type
- Disinfection Products
- Surface disinfectants
- Hand sanitizers
- Disinfectant wipes
- Others
- Personal Protective Equipment
- Masks (surgical, N95, respirators)
- Gloves (latex, nitrile, vinyl)
- Gowns and coveralls
- Face shields and goggles
- Sterilization Equipment
- Autoclaves
- Ultrasonic cleaners
- Irradiation equipment
- Monitoring and Surveillance Products
- Environmental monitoring systems
- Microbial air samplers
- Others
End-Use
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- DIagnostic Laboratories
- Ambulatory Surgical Centers
- Others
Regional Analysis
In 2023, North America retained its leading position in the Infection Control and Biosafety Products Market, accounting for over 35.1% of the global share, valued at approximately USD 19.9 billion. This dominance is primarily attributed to the region’s well-established healthcare infrastructure, stringent regulatory frameworks, and ongoing investments in infection prevention technologies. Robust R&D activities continue to drive innovation across disinfection and biosafety product lines.
Europe also secured a significant market share, supported by proactive governmental policies aimed at reducing hospital-acquired infections and enhancing patient safety. Increased healthcare expenditure across the region has further accelerated the adoption of advanced infection control solutions in hospitals and laboratories.
The Asia-Pacific region is emerging as the fastest-growing market, driven by rapid improvements in healthcare infrastructure and heightened awareness of biosafety measures among healthcare professionals. Countries such as China, India, and Japan are leading this expansion, backed by government funding, modernization of medical facilities, and strong regulatory push for infection control compliance.
Regions such as Latin America and the Middle East & Africa are witnessing moderate growth, supported by increased healthcare investments and the gradual implementation of international infection control standards. These trends collectively indicate a steady global expansion, propelled by rising awareness and stringent infection prevention policies worldwide.
Emerging Trends
- Expansion of National IPC Programmes: A 2023–2024 WHO survey found that 71% of countries reported having an active infection prevention and control (IPC) programme. However, only 6% met all WHO minimum standards for IPC, underscoring a drive to strengthen national policies and resources to close this gap by 2030.
- Emphasis on Hand Hygiene: WHO data indicate that proper hand hygiene and basic cleaning can prevent up to 70% of healthcare associated infections (HAIs). This has spurred wider availability and use of alcohol based hand rubs and standardized hand washing protocols across health facilities.
- Adoption of “No Touch” Disinfection Technologies: Healthcare settings are increasingly deploying UVC and vaporized hydrogen peroxide systems. Studies demonstrate that adding UVC to standard cleaning can reduce Clostridioides difficile and multidrug resistant organism incidence by 22–53% in some hospitals.
- Digital Monitoring and Data Driven IPC: The 2024 WHO Global Action Plan on IPC emphasizes digital tools and indicators. Ninety four countries participated in recent IPC implementation surveys, reflecting growing use of electronic monitoring systems and data dashboards to track compliance and outbreak risks.
- Enhanced Biosafety in Laboratories: The 6th edition of CDC’s Biosafety in Microbiological and Biomedical Laboratories (BMBL), revised June 2020, introduced updated risk assessment frameworks and guidelines for BSL 3 and BSL 4 facilities. This trend highlights the need for advanced biosafety cabinets and secure lab designs to contain emerging pathogens.
Use Cases
- Alcohol Based Hand Rubs: Widely used at the point of care, these dispensers support hand hygiene protocols that can prevent 70 % of HAIs when used correctly before and after patient contact.
- Chemical High Level Disinfectants: Products such as 2% glutaraldehyde and peracetic acid reliably inactivate C.difficile spores within 5–20 minutes, ensuring safe reuse of endoscopes and other semicritical medical instruments.
- Environmental Sampling Kits: CDC’s guidelines for surface and air sampling in healthcare facilities enable infection control teams to map contamination hotspots, guiding targeted cleaning and reducing environmental pathogen reservoirs.
- Biosafety Cabinets and Isolators: Essential in microbiology and clinical labs, Class II and III biosafety cabinets conform to CDC/NIH BMBL standards. They protect workers and prevent release of high risk agents during diagnostic or research procedures.
Conclusion
The global infection control and biosafety products market is set to experience sustained growth, driven by rising infection prevention awareness, stringent regulatory frameworks, and increasing healthcare investments worldwide. With market value projected to reach USD 130.8 billion by 2033, demand is especially strong for disinfection products and PPE across hospitals and laboratories.
Emerging trends such as digital IPC monitoring, “no-touch” disinfection technologies, and enhanced biosafety infrastructure further support market expansion. Regional growth is led by North America, with Asia-Pacific showing rapid advancement. Continued global efforts to reduce healthcare-associated infections will remain central to driving innovation and adoption across the sector.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
